United Therapeutics (UTHR) Cash from Investing Activities Growth (3y) (2012 - 2026)
United Therapeutics (UTHR) Cash from Investing Activities Growth (3y) (2012 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 8.16% |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 26.15% |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 51.85% |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 75.05% |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 33.33% |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | -129.09% |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | -2.94% |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 135.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 75.05% |
| Dec 31, 2025 | -6.33% |
| Sep 30, 2025 | 51.81% |
| Jun 30, 2025 | -21.07% |
| Mar 31, 2025 | 22.89% |
| Dec 31, 2024 | 14.31% |
| Sep 30, 2024 | 21.32% |
| Jun 30, 2024 | -17.83% |
| Mar 31, 2024 | 391.47% |
| Dec 31, 2023 | 38.55% |
| Sep 30, 2023 | -4.87% |
| Jun 30, 2023 | 15.41% |
| Mar 31, 2023 | -100.09% |
| Dec 31, 2022 | -69.38% |
| Sep 30, 2022 | 31.98% |
| Jun 30, 2022 | -58.30% |
| Mar 31, 2022 | -81.28% |
| Dec 31, 2021 | -39.45% |
| Sep 30, 2021 | 10.58% |
| Jun 30, 2021 | 48.59% |